From: RNA-based therapies: A cog in the wheel of lung cancer defense
Drug combination
Affected Pathway
References
Custirsen + gemcitabine + cisplatin
Clusterin
[288]
Aprinocarsen + gemcitabine + cisplatin
PKC-a
[300, 303, 304]
Imetelstat + bevacizumab
Telomerase
[286]
LY2181308 + docetaxel
Survivin
[305]
Oblimersen + paclitaxel
Bcl2
[283]
Oblimersen + carboplatin + etoposide
[285]